Combined vascular endothelial growth factor receptor and Epidermal Growth Factor Receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance

George N. Naumov, Monique B. Nilsson, Tina Cascone, Alexandra Briggs, Oddbjorn Straume, Lars A. Akslen, Eugene Lifshits, Lauren Averett Byers, Li Xu, Hua Kang Wu, Pasi Jänne, Susumu Kobayashi, Balazs Halmos, Daniel Tenen, Xi M. Tang, Jeffrey Engelman, Beow Yeap, Judah Folkman, Bruce E. Johnson, John V. Heymach

Research output: Contribution to journalArticle

198 Citations (Scopus)

Abstract

Purpose: The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) gefitinib and erlotinib benefit some non-small cell lung cancer (NSCLC) patients, but mostdo notrespond (primary resistance) and those who initially respond eventually progress (acquired resistance). EGFR TKI resistance is not completely understood and has been associated with certain EGFR and K-RAS mutations and MET amplification. Experimental Design: We hypothesized that dual inhibition of the vascular endothelial growth factor (VEGF) and EGFR pathways may overcome primary and acquired resistance. We investigated the VEGF receptor/EGFR TKI vandetanib, and the combination of bevacizumab and erlotinib in vivo using xenograft models of EGFR TKI sensitivity, primary resistance, and three models of acquired resistance, including models with mutated K-RAS and secondary EGFR T790M mutation. Results: Vandetanib, gefitinib, and erlotinib had similar profiles of in vitro activity and caused sustained tumor regressions in vivo in the sensitive HCC827 model. In all four resistant models, vandetanib and bevacizumab/erlotinib were significantly more effective than erlotinib or gefitinib alone. Erlotinib resistance was associated with a rise in both host and tumor-derived VEGF but not EGFR secondary mutations in the KRAS mutant-bearing A549 xenografts. Dual inhibition reduced tumor endothelial proliferation compared with VEGF or EGFR blockade alone, suggesting that the enhanced activity of dual inhibition is due at least in part to antiendothelial effects. Conclusion: These studies suggest that erlotinib resistance may be associated with a rise in both tumor cell and host stromal VEGF and that combined blockade of the VEGFR and EGFR pathways can abrogate primary or acquired resistance to EGFR TKIs. This approach merits further evaluation in NSCLC patients.

Original languageEnglish (US)
Pages (from-to)3484-3494
Number of pages11
JournalClinical Cancer Research
Volume15
Issue number10
DOIs
StatePublished - May 15 2009
Externally publishedYes

Fingerprint

Vascular Endothelial Growth Factor Receptor
Epidermal Growth Factor Receptor
Heterografts
Growth
Neoplasms
Protein-Tyrosine Kinases
Vascular Endothelial Growth Factor A
Non-Small Cell Lung Carcinoma
Mutation
Stromal Cells
Erlotinib Hydrochloride
Research Design

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Combined vascular endothelial growth factor receptor and Epidermal Growth Factor Receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance. / Naumov, George N.; Nilsson, Monique B.; Cascone, Tina; Briggs, Alexandra; Straume, Oddbjorn; Akslen, Lars A.; Lifshits, Eugene; Byers, Lauren Averett; Xu, Li; Wu, Hua Kang; Jänne, Pasi; Kobayashi, Susumu; Halmos, Balazs; Tenen, Daniel; Tang, Xi M.; Engelman, Jeffrey; Yeap, Beow; Folkman, Judah; Johnson, Bruce E.; Heymach, John V.

In: Clinical Cancer Research, Vol. 15, No. 10, 15.05.2009, p. 3484-3494.

Research output: Contribution to journalArticle

Naumov, GN, Nilsson, MB, Cascone, T, Briggs, A, Straume, O, Akslen, LA, Lifshits, E, Byers, LA, Xu, L, Wu, HK, Jänne, P, Kobayashi, S, Halmos, B, Tenen, D, Tang, XM, Engelman, J, Yeap, B, Folkman, J, Johnson, BE & Heymach, JV 2009, 'Combined vascular endothelial growth factor receptor and Epidermal Growth Factor Receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance', Clinical Cancer Research, vol. 15, no. 10, pp. 3484-3494. https://doi.org/10.1158/1078-0432.CCR-08-2904
Naumov, George N. ; Nilsson, Monique B. ; Cascone, Tina ; Briggs, Alexandra ; Straume, Oddbjorn ; Akslen, Lars A. ; Lifshits, Eugene ; Byers, Lauren Averett ; Xu, Li ; Wu, Hua Kang ; Jänne, Pasi ; Kobayashi, Susumu ; Halmos, Balazs ; Tenen, Daniel ; Tang, Xi M. ; Engelman, Jeffrey ; Yeap, Beow ; Folkman, Judah ; Johnson, Bruce E. ; Heymach, John V. / Combined vascular endothelial growth factor receptor and Epidermal Growth Factor Receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance. In: Clinical Cancer Research. 2009 ; Vol. 15, No. 10. pp. 3484-3494.
@article{94f5ee8344d049ee8aafc031f6673d41,
title = "Combined vascular endothelial growth factor receptor and Epidermal Growth Factor Receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance",
abstract = "Purpose: The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) gefitinib and erlotinib benefit some non-small cell lung cancer (NSCLC) patients, but mostdo notrespond (primary resistance) and those who initially respond eventually progress (acquired resistance). EGFR TKI resistance is not completely understood and has been associated with certain EGFR and K-RAS mutations and MET amplification. Experimental Design: We hypothesized that dual inhibition of the vascular endothelial growth factor (VEGF) and EGFR pathways may overcome primary and acquired resistance. We investigated the VEGF receptor/EGFR TKI vandetanib, and the combination of bevacizumab and erlotinib in vivo using xenograft models of EGFR TKI sensitivity, primary resistance, and three models of acquired resistance, including models with mutated K-RAS and secondary EGFR T790M mutation. Results: Vandetanib, gefitinib, and erlotinib had similar profiles of in vitro activity and caused sustained tumor regressions in vivo in the sensitive HCC827 model. In all four resistant models, vandetanib and bevacizumab/erlotinib were significantly more effective than erlotinib or gefitinib alone. Erlotinib resistance was associated with a rise in both host and tumor-derived VEGF but not EGFR secondary mutations in the KRAS mutant-bearing A549 xenografts. Dual inhibition reduced tumor endothelial proliferation compared with VEGF or EGFR blockade alone, suggesting that the enhanced activity of dual inhibition is due at least in part to antiendothelial effects. Conclusion: These studies suggest that erlotinib resistance may be associated with a rise in both tumor cell and host stromal VEGF and that combined blockade of the VEGFR and EGFR pathways can abrogate primary or acquired resistance to EGFR TKIs. This approach merits further evaluation in NSCLC patients.",
author = "Naumov, {George N.} and Nilsson, {Monique B.} and Tina Cascone and Alexandra Briggs and Oddbjorn Straume and Akslen, {Lars A.} and Eugene Lifshits and Byers, {Lauren Averett} and Li Xu and Wu, {Hua Kang} and Pasi J{\"a}nne and Susumu Kobayashi and Balazs Halmos and Daniel Tenen and Tang, {Xi M.} and Jeffrey Engelman and Beow Yeap and Judah Folkman and Johnson, {Bruce E.} and Heymach, {John V.}",
year = "2009",
month = "5",
day = "15",
doi = "10.1158/1078-0432.CCR-08-2904",
language = "English (US)",
volume = "15",
pages = "3484--3494",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "10",

}

TY - JOUR

T1 - Combined vascular endothelial growth factor receptor and Epidermal Growth Factor Receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance

AU - Naumov, George N.

AU - Nilsson, Monique B.

AU - Cascone, Tina

AU - Briggs, Alexandra

AU - Straume, Oddbjorn

AU - Akslen, Lars A.

AU - Lifshits, Eugene

AU - Byers, Lauren Averett

AU - Xu, Li

AU - Wu, Hua Kang

AU - Jänne, Pasi

AU - Kobayashi, Susumu

AU - Halmos, Balazs

AU - Tenen, Daniel

AU - Tang, Xi M.

AU - Engelman, Jeffrey

AU - Yeap, Beow

AU - Folkman, Judah

AU - Johnson, Bruce E.

AU - Heymach, John V.

PY - 2009/5/15

Y1 - 2009/5/15

N2 - Purpose: The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) gefitinib and erlotinib benefit some non-small cell lung cancer (NSCLC) patients, but mostdo notrespond (primary resistance) and those who initially respond eventually progress (acquired resistance). EGFR TKI resistance is not completely understood and has been associated with certain EGFR and K-RAS mutations and MET amplification. Experimental Design: We hypothesized that dual inhibition of the vascular endothelial growth factor (VEGF) and EGFR pathways may overcome primary and acquired resistance. We investigated the VEGF receptor/EGFR TKI vandetanib, and the combination of bevacizumab and erlotinib in vivo using xenograft models of EGFR TKI sensitivity, primary resistance, and three models of acquired resistance, including models with mutated K-RAS and secondary EGFR T790M mutation. Results: Vandetanib, gefitinib, and erlotinib had similar profiles of in vitro activity and caused sustained tumor regressions in vivo in the sensitive HCC827 model. In all four resistant models, vandetanib and bevacizumab/erlotinib were significantly more effective than erlotinib or gefitinib alone. Erlotinib resistance was associated with a rise in both host and tumor-derived VEGF but not EGFR secondary mutations in the KRAS mutant-bearing A549 xenografts. Dual inhibition reduced tumor endothelial proliferation compared with VEGF or EGFR blockade alone, suggesting that the enhanced activity of dual inhibition is due at least in part to antiendothelial effects. Conclusion: These studies suggest that erlotinib resistance may be associated with a rise in both tumor cell and host stromal VEGF and that combined blockade of the VEGFR and EGFR pathways can abrogate primary or acquired resistance to EGFR TKIs. This approach merits further evaluation in NSCLC patients.

AB - Purpose: The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) gefitinib and erlotinib benefit some non-small cell lung cancer (NSCLC) patients, but mostdo notrespond (primary resistance) and those who initially respond eventually progress (acquired resistance). EGFR TKI resistance is not completely understood and has been associated with certain EGFR and K-RAS mutations and MET amplification. Experimental Design: We hypothesized that dual inhibition of the vascular endothelial growth factor (VEGF) and EGFR pathways may overcome primary and acquired resistance. We investigated the VEGF receptor/EGFR TKI vandetanib, and the combination of bevacizumab and erlotinib in vivo using xenograft models of EGFR TKI sensitivity, primary resistance, and three models of acquired resistance, including models with mutated K-RAS and secondary EGFR T790M mutation. Results: Vandetanib, gefitinib, and erlotinib had similar profiles of in vitro activity and caused sustained tumor regressions in vivo in the sensitive HCC827 model. In all four resistant models, vandetanib and bevacizumab/erlotinib were significantly more effective than erlotinib or gefitinib alone. Erlotinib resistance was associated with a rise in both host and tumor-derived VEGF but not EGFR secondary mutations in the KRAS mutant-bearing A549 xenografts. Dual inhibition reduced tumor endothelial proliferation compared with VEGF or EGFR blockade alone, suggesting that the enhanced activity of dual inhibition is due at least in part to antiendothelial effects. Conclusion: These studies suggest that erlotinib resistance may be associated with a rise in both tumor cell and host stromal VEGF and that combined blockade of the VEGFR and EGFR pathways can abrogate primary or acquired resistance to EGFR TKIs. This approach merits further evaluation in NSCLC patients.

UR - http://www.scopus.com/inward/record.url?scp=66149163097&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=66149163097&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-08-2904

DO - 10.1158/1078-0432.CCR-08-2904

M3 - Article

C2 - 19447865

AN - SCOPUS:66149163097

VL - 15

SP - 3484

EP - 3494

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 10

ER -